In 2022, Prottermin, a drug for Parkinson’s disease developed in Novosibirsk Institute of Organic Chemistry named after N. N. Vorozhtsov (NIOH) of SB RAS, completed the first phase of clinical trials. The result turned out to be promising: the drug demonstrated high antiparkinsonian activity. Nevertheless, the second phase has not started for lack of funding, Interfax reports.
According to Nariman Salakhutdinov, the head of the NIOH laboratory of physiologically active substances, funding for the first phase of clinical trials was provided for by a Novosibirsk businessman suffering from Parkinson’s, but “now no sources like that are available.”
The researcher specified that they need 400 million rubles for the trials. Documents for the second phase of the drug trials have been submitted to the Ministry of Health of the Russian Federation.
At the moment, the only drug available in Russia for the treatment of Parkinson’s disease is Levodopa, which has several significant drawbacks. The main problem is that its effectiveness decreases after three or four years of use.
